Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin.

Mauer J, Chaurasia B, Goldau J, Vogt MC, Ruud J, Nguyen KD, Theurich S, Hausen AC, Schmitz J, Brönneke HS, Estevez E, Allen TL, Mesaros A, Partridge L, Febbraio MA, Chawla A, Wunderlich FT, Brüning JC.

Nat Immunol. 2014 May;15(5):423-30. doi: 10.1038/ni.2865.

2.

IL-6 strikes a balance in metabolic inflammation.

Covarrubias AJ, Horng T.

Cell Metab. 2014 Jun 3;19(6):898-9. doi: 10.1016/j.cmet.2014.05.009.

3.

A key regulatory role for Vav1 in controlling lipopolysaccharide endotoxemia via macrophage-derived IL-6.

Zenker S, Panteleev-Ivlev J, Wirtz S, Kishimoto T, Waldner MJ, Ksionda O, Tybulewicz VL, Neurath MF, Atreya I.

J Immunol. 2014 Mar 15;192(6):2830-6. doi: 10.4049/jimmunol.1300157.

4.

Chitohexaose activates macrophages by alternate pathway through TLR4 and blocks endotoxemia.

Panda SK, Kumar S, Tupperwar NC, Vaidya T, George A, Rath S, Bal V, Ravindran B.

PLoS Pathog. 2012;8(5):e1002717. doi: 10.1371/journal.ppat.1002717.

5.

Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action.

Wunderlich FT, Ströhle P, Könner AC, Gruber S, Tovar S, Brönneke HS, Juntti-Berggren L, Li LS, van Rooijen N, Libert C, Berggren PO, Brüning JC.

Cell Metab. 2010 Sep 8;12(3):237-49. doi: 10.1016/j.cmet.2010.06.011.

6.

Lack of interleukin-1 receptor I (IL-1RI) protects mice from high-fat diet-induced adipose tissue inflammation coincident with improved glucose homeostasis.

McGillicuddy FC, Harford KA, Reynolds CM, Oliver E, Claessens M, Mills KH, Roche HM.

Diabetes. 2011 Jun;60(6):1688-98. doi: 10.2337/db10-1278.

7.

Immunometabolism: IL-6, the resistance fighter.

Bordon Y.

Nat Rev Immunol. 2014 May;14(5):282-3. doi: 10.1038/nri3670. No abstract available.

PMID:
24751953
8.

Deficiency of the leukotriene B4 receptor, BLT-1, protects against systemic insulin resistance in diet-induced obesity.

Spite M, Hellmann J, Tang Y, Mathis SP, Kosuri M, Bhatnagar A, Jala VR, Haribabu B.

J Immunol. 2011 Aug 15;187(4):1942-9. doi: 10.4049/jimmunol.1100196.

9.

The good, the bad, and the ugly of interleukin-6 signaling.

Fuster JJ, Walsh K.

EMBO J. 2014 Jul 1;33(13):1425-7. doi: 10.15252/embj.201488856. No abstract available.

10.

Myeloid cell-restricted insulin receptor deficiency protects against obesity-induced inflammation and systemic insulin resistance.

Mauer J, Chaurasia B, Plum L, Quast T, Hampel B, Blüher M, Kolanus W, Kahn CR, Brüning JC.

PLoS Genet. 2010 May 6;6(5):e1000938. doi: 10.1371/journal.pgen.1000938.

11.

Obesity and IL-6 interact in modulating the response to endotoxemia in mice.

Pini M, Castellanos KJ, Rhodes DH, Fantuzzi G.

Cytokine. 2013 Jan;61(1):71-7. doi: 10.1016/j.cyto.2012.08.027.

12.

Countering inflammatory signals in obesity.

Reilly SM, Saltiel AR.

Nat Immunol. 2014 May;15(5):410-1. doi: 10.1038/ni.2874. No abstract available.

PMID:
24747704
13.

CD11b regulates obesity-induced insulin resistance via limiting alternative activation and proliferation of adipose tissue macrophages.

Zheng C, Yang Q, Xu C, Shou P, Cao J, Jiang M, Chen Q, Cao G, Han Y, Li F, Cao W, Zhang L, Zhang L, Shi Y, Wang Y.

Proc Natl Acad Sci U S A. 2015 Dec 29;112(52):E7239-48. doi: 10.1073/pnas.1500396113.

14.

A novel regulator of macrophage activation: miR-223 in obesity-associated adipose tissue inflammation.

Zhuang G, Meng C, Guo X, Cheruku PS, Shi L, Xu H, Li H, Wang G, Evans AR, Safe S, Wu C, Zhou B.

Circulation. 2012 Jun 12;125(23):2892-903. doi: 10.1161/CIRCULATIONAHA.111.087817.

15.

Adenosine augments IL-10-induced STAT3 signaling in M2c macrophages.

Koscsó B, Csóka B, Kókai E, Németh ZH, Pacher P, Virág L, Leibovich SJ, Haskó G.

J Leukoc Biol. 2013 Dec;94(6):1309-15. doi: 10.1189/jlb.0113043.

16.

CTLA-4Ig immunotherapy of obesity-induced insulin resistance by manipulation of macrophage polarization in adipose tissues.

Fujii M, Inoguchi T, Batchuluun B, Sugiyama N, Kobayashi K, Sonoda N, Takayanagi R.

Biochem Biophys Res Commun. 2013 Aug 16;438(1):103-9. doi: 10.1016/j.bbrc.2013.07.034.

PMID:
23872146
17.

The Prostaglandin E2 Receptor EP4 Regulates Obesity-Related Inflammation and Insulin Sensitivity.

Yasui M, Tamura Y, Minami M, Higuchi S, Fujikawa R, Ikedo T, Nagata M, Arai H, Murayama T, Yokode M.

PLoS One. 2015 Aug 26;10(8):e0136304. doi: 10.1371/journal.pone.0136304.

18.

MAP3K8 (TPL2/COT) affects obesity-induced adipose tissue inflammation without systemic effects in humans and in mice.

Ballak DB, van Essen P, van Diepen JA, Jansen H, Hijmans A, Matsuguchi T, Sparrer H, Tack CJ, Netea MG, Joosten LA, Stienstra R.

PLoS One. 2014 Feb 24;9(2):e89615. doi: 10.1371/journal.pone.0089615.

19.

Regulation of adipose tissue T cell subsets by Stat3 is crucial for diet-induced obesity and insulin resistance.

Priceman SJ, Kujawski M, Shen S, Cherryholmes GA, Lee H, Zhang C, Kruper L, Mortimer J, Jove R, Riggs AD, Yu H.

Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):13079-84. doi: 10.1073/pnas.1311557110.

20.

The complement anaphylatoxin C5a receptor contributes to obese adipose tissue inflammation and insulin resistance.

Phieler J, Chung KJ, Chatzigeorgiou A, Klotzsche-von Ameln A, Garcia-Martin R, Sprott D, Moisidou M, Tzanavari T, Ludwig B, Baraban E, Ehrhart-Bornstein M, Bornstein SR, Mziaut H, Solimena M, Karalis KP, Economopoulou M, Lambris JD, Chavakis T.

J Immunol. 2013 Oct 15;191(8):4367-74. doi: 10.4049/jimmunol.1300038.

Items per page

Supplemental Content

Support Center